Key facts
- Ektah’s last known valuation is $6.6M (Mar 2025).
- It has raised $4.4M; the latest was Accelerator/Incubator in Nov 2025.
- Notable investors include La French Tech, EIT Food, UI Investissement, Capital Cell, DECA-BFC — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Ektah
- ·The full record, as it builds
Funding rounds
No funding rounds for Ektah are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ektah
Operator of a biotechnology company intended to develop therapeutics to reduce body weight. The company's platform identifies and develops novel molecules that target specific biological pathways involved in weight regulation, enabling people to access innovative treatments for obesity.
- Sector
- Healthcare
- HQ
- Dijon, France
- Founded
- 2021
- Employees
- 7
- Website
- ektah.com/
- Ownership
- Privately Held (backing)
Ektah doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ektah shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ektah in its N-PORT filings yet. We sweep new filings monthly.